| Name | Title | Contact Details |
|---|---|---|
Eric Giesing |
Chief Commercial Officer (CCO) | Profile |
`Akrevia` is derived from the Greek word for `precision`, which reflects our mission to precisely deliver the activity of potent, tailored immunotherapies exactly where it’s needed.
Metavention is a venture-backed medical device company founded in 2012 that is developing a novel glucose control therapy for patients with type 2 diabetes. Metabolic Neuromodulation Therapy (MNT) is a simple cardiovascular procedure intended to modulate sympathetic nervous system activity in patients with Type 2 diabetes for the purpose of lowering blood glucose levels. MNT was developed based on published scientific data and extensive animal studies suggesting a link between elevated sympathetic nerve activity in the metabolic system and increased levels of blood glucose. MNT is currently being studied in human clinical trials and represents a potentially important new treatment option for patients with Type 2 Diabetes.
St. Patricks Hospital is a Missoula, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Thrasos is a private, clinical-stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. The company's lead compound, THR-184 is currently being evaluated in a Phase 2 clinical study for the prevention of AKI in patients undergoing cardiac surgery. Thrasos is also developing compounds for diabetic nephropathy, a major cause of chronic kidney disease